sfondo pallini
ovale top ovale left ovale right

therapies for
the treatment
of rare diseases

into blood

Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood

Latest News

View all

EryDel to Present at A-T
Society Family Weekend

July 20, 2019

Read more

Luca Benatti, President and Chief Executive Officer, and Stan Musial, Chief ...

June 10, 2019

Read more
img ufficio

Our Technology

EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.


A late Stage
and Broad Pipeline

tabella tabella More details

Our People

About us
luca-benatti +

Luca Benatti
Chief Executive Officer

giovanni-mambrini +

Giovanni Mambrini
Chief Operating Officer

ronan-gannon +

Ronan Gannon
Chief Commercial Officer

stan-musial +

Stan Musial
Chief Financial Officer

guenter-r-janhofer +

Guenter R. Janhofer
Chief Medical Officer

alyssa-wyant +

Alyssa Wyant
Senior Vice President Regulatory Affairs